MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

COMPOSITIONS AND METHODS OF PREPARATION COMPRISING AMOXICILLIN AND POTASSIUM CLAVULANATE, OR SALTS THEREOF

Korea Health Industry Development Institute
We have developed the tablet for suspension containing Amoxicillin and Potassium Clavulanate, equivalent to GSK’s Augmentin® Suspension, This product is much superior to the reference product in terms of stability during storage and don’t require stor

Mechanism of action

Remarkably stability of main component, Suitable administration, Easiness of Formulation, Simple portable tablet

Full description

Technology Platform

The core technology of GLPT is to provide promising dispersible tablet.  The dispersible tablet of this invention has some advantages: easy formulation procedures and high solubility in water.

Background and unmet needs: Amoxicillin is a representative of β-lactam antibiotic substances and has efficacies on bacterial infection. Potassium clavulanate has a role of expanding anti-bacterial spectrum of amoxicillin as a function to inhibit β-lactamase. Mixture of amoxicillin/potassium clavulanate has been already developed and commercially utilized as a representative product, Augmentin®.

Discovery and Achievements: Mixture of amoxicillin/potassium clavulanate could be commercially purchased, which contains forms of tablet, dry syrup and injection. Among them, dry syrup was used in a form of suspension solution dissolved in a constant amount of water. However, dry syrup is prone to deterioration according to resuspended or storage conditions.

To overcome this problem, the GLPT has made intensive studies to develop an dispersible tablet for improving administration, formulation and solubility. As results, the GLPT has discovered the simple portable dispersible tablet of this invention with great stability, exact administration, easy formulation and high solubility in water.

TABLE 1. Composition of dispersible tablet of this invention

Classification

Components

Disintegrant

A and B

Filler

Microcrystalline cellulose and silicon dioxide

Glydent

Magnesium stearate

Sweetner

Acesulfame potassium

Pertume

Strawberry flavor cotton

 

The dispersible tablet of this invention was composed of disintegrant, filler, glydent, sweetner and pertume. The dispersible tablet of this invention was fabricated to be resuspended by disintegration in small amount of water within 1 min.

TABLE 2. Specification

Item

Standard

Reference

Appearance

White or pale yellow circular tablet

 

Identification

Positive

 

Disintegration Time

Within 3 min

15-25°C in pure water

Water content

> 9.0%

Karl Fisher method

Assay

90-120%

 

 

TABLE 3. Stability Test under Long-term Storage Conditions and Accelerated Conditions

Period

Storage

Conditions

Appearance

Confirm Test

Disintegration Time (sec)

Water content

Content (%)

Amoxicillin

Potassium clavulanate

Standard

White~pale yellow

Positive

Within 3 min

> 9.0%

90-120%

90-120%

Initial

-

fit

positive

39

6.88

103.16

105.57

1 month

25°C/RH60%

fit

positive

36

7.02

Development status

Early Stage

Patent information

The GLPT has been already filed for a patent application in Korea. In addition, it will be filed for a PCT application in the near future.

Type of business relationship sought

development collaboration, or non-exclusive or exclusive licensing agreement

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us